

08/13/20

## Vaccine Booster Tip Sheet

### 1. Who decided that a Booster Vaccine could be given?

[FDA approval on 8/12/21](#)

[ACIP \(Advisory Committee on Immunization Practices\) approval on 8/13/2021](#)

### 2. Who Qualifies for a booster mRNA vaccine?

- a. Active treatment for solid tumor and hematologic malignancies
- b. Receipt of solid-organ transplant & taking immunosuppressive therapy \*see appendix 1
- c. Receipt of CAR-T-Cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy)
- d. Moderate or severe primary immunodeficiency (e.g., DiGeorge Syndrome, Wiskott-Aldrich syndrome)
- e. Advanced or untreated HIV
- f. Active treatment with:
  - i. High dose systemic corticosteroids ( $\geq 20$ mg prednisone or equivalent per day) - or  $\geq 2$ mg/kg per day)
  - ii. Alkylating agents (cyclophosphamide)
  - iii. Antimetabolites (azathioprine, 6-MP, MTX)
  - iv. Transplant-related immunosuppressive drugs (cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil)
  - v. Cancer chemotherapeutic agents classified as severely immunosuppressive
  - vi. TNF blockers (etanercept, adalimumab, certolizumab pegol, golimumab, infliximab)
  - vii. Other biologic agents that are immunosuppressive or immunomodulatory (thymoglobulin, alemtuzumab, rituxumab)
- g. Medical Conditions with Varied Immunodeficiency
  - i. Sickle Cell Disease
  - ii. Chronic dialysis patients; End Stage Renal Disease
  - iii. Chronic Liver Disease

### 3. How is the registration process different for patients seeking a booster?


- a. A pre-assessment form will need to be completed by the patient along with the attestation
- b. Patient can schedule a booster shot or walk into clinic
- c. Schedule patient for a first dose at this time until the CareLink build is completed

### 4. How is the administration of the vaccine different for booster doses?


- a. Same administration and dosage as initial vaccine administration

### 5. What vaccine should be given for the booster

- a. If they received Pfizer initially, they should receive Pfizer (12 years and up)
- b. If they received Moderna initially, they should receive Moderna (18 years and up)




- c. If they received Johnson & Johnson initially, they should NOT receive a booster at this time.
  
- 6. How long after the 2<sup>nd</sup> vaccine dose should the patient wait before getting the booster?**
  - a. A minimum of 4 weeks (28 days)
  
- 7. How is the documentation of the vaccine different for booster doses?**
  - a. Enter in third dose into VAMS and Carelink as usual, ignore pop-up warning about third dose. This will be updated once EPIC has sent us the update
  - b. Do NOT schedule a 4<sup>th</sup> dose
  - c. CDC card: Document on the front of the card if possible, if that is not possible document on the back of the CDC card with the same information as with other doses: Lot #, manufacturer, location of vaccine, date of vaccination
  
- 8. What are some conditions that do NOT qualify for a booster at this time?**
  - a. Short term daily steroids, or daily therapy <20mg per day
  - b. Steroid inhalers, topic steroids, intra-articular steroid injection
  - c. >1 month since stopping high-dose systemic steroids
  - d. HIV patients without severe immunosuppression (usually based on CD4+ T-cell counts)
  - e. Autoimmune conditions that are stable and not being treated with immunosuppressive or immunomodulatory medications
  - f. Pregnancy
  - g. Diabetes
  - h. Congestive Heart Failure
  - i. Chronic lung disease
  - j. Obesity
  
- 9. Are there some classes of patients who do not qualify for a booster at this time (unless they have other stated conditions above)?**
  - a. Healthcare Workers
  - b. Long-term care facility
  - c. Elderly
  
- 10. How does a patient prove they have an immunocompromising condition?**
  - a. They attest to having one of the above conditions
  
- 11. Do patients need a doctor's note to prove they have an immunocompromising condition or get a booster shot?**
  - a. No, they need to attest to having one of the above immunocompromising condition
  
- 12. What is the dose for the for the booster vaccine dose?**
  - a. Dose amount and administration is the same as for 1st and 2nd doses



## Appendix 1:

GENERIC NAME	TRADE NAME	MECHANISM/TARGET OF ACTION
Abatacept	Orencia	Anti-CD28/CTLA-4
Adalimumab	Humira	TNF blocker
Alemtuzumab	Campath	Anti-CD52
Anakinra	Kineret	IL-1 antagonist
Atezolizumab	Tecentriq	PD- L1
Avelumab	Bavencio	PD- L1
Basiliximab	Simulect	IL-2R/CD25
Belatacept	Nulojix	CTLA-4
Bevacizumab	Avastin	VEGF
Certolizumab pegol	Cimzia	TNF blocker
Cetuximab	Erbitux	EGFR
Dasatinib	Sprycel	Bcr-Abl tyrosine kinase inhibitor
Dimethyl fumarate	Tecfidera	Activates the nuclear erythroid 2-related factor 2 transcriptional pathway
Etanercept	Enbrel	TNF blocker
Fingolimod	Gilenya	Sphingosine 1-phosphate receptor modulator
Glatiramer acetate	Copaxone	Immunomodulatory; target unknown
Golimumab	Simponi	TNF blocker
Ibritumomab tiuxetan	Zevalin	CD20 with radioisotope
Ibrutinib	Imbruvica	Tyrosine kinase inhibitor
Imatinib mesylate	Gleevec, STI 571	Signal transduction inhibitor/protein-tyrosine kinase inhibitor



# COVID-19

Infliximab	Remicade	TNF blocker
Interferon alfa	Pegasys, PegIntron	Block hepatitis C viral replication
Interferon beta-1a	Avonex, Rebif	Immunomodulatory; target unknown
Interferon beta-1b	Betaseron	Immunomodulatory; target unknown
Natalizumab	Tsabri	$\alpha$ 4-integrin
Nivolumab	Opdivo	PD-1
Ofatumumab	Arzerra	CD20
Panitumumab	Vectibix	EGFR
Pembrolizumab	Keytruda	PD-1
Lenalidomide	Revlimid	Immunomodulatory
Rilonacept	Arcalyst	IL-1
Rituximab	Rituxan	CD20
Sarilumab	Kevzara	IL- 6
Secukinumab	Cosentyx	IL-17A
Sunitinib malate	Sutent	Multikinase inhibitor
Tocilizumab	Actemra	IL-6
Tofacitinib	Xeljanz	JAK kinase inhibitor
Trastuzumab	Herceptin	Human EGFR 2 (HER2)
Ustekinumab	Stelara	IL-12, IL-23
Vedolizumab	Entyvio	Binds integrin $\alpha$ 4 $\beta$ 7